The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Insurer Updates

Insurer Updates

October 1, 2009 • By Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

IFA Codes
Quest: 38318
LabCorp: 164947

You Might Also Like
  • Some Lupus Tests Yield False Results
  • New Study Reveals Limitations in ANA Test Kits for Lupus
  • Is Your Office Lab Up to Par?
Explore This Issue
October 2009
Also By This Author
  • The 2015 ACR/ARHP Annual Meeting Call for Proposals

WellPoint, BCBS Change Policy at ACR’s Request

After receiving a letter from the ACR, WellPoint agreed that it is no longer necessary to request a new authorization if moving a patient on etanercept to a different dosing schedule (e.g., from 50 mg to 25 mg twice weekly). In addition, WellPoint revised the Enbrel PAB form to remove the question regarding “systemic malignancy within the last five years.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Additionally, after receiving a letter from the ACR, Blue Cross and Blue Shield of Massachusetts has agreed to update its policy in the fall to cover anti-CCP testing for rheumatoid arthritis, stating, “anti-CCP testing is now considered medically necessary for the diagnosis of rheumatoid arthritis.”

The ACR has long advocated for its members’ issues relating to health plan policy and has had many successes in this area. Through letters sent by CORC, positive changes have occurred.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Use Correct Lab Code to Get Correct ANA Test

Immunofluorescence assay (IFA) continues to be the gold standard to test for antinuclear antibodies (ANAs), and physicians can order these tests from commercial laboratories.

During the past decade, commercial clinical laboratories have adopted a wide variety of new tests, including solid-phase assays, for the detection of ANAs. Some commercial laboratories have adopted these new assays to replace traditional “gold standard” indirect immunofluorescence tests to screen for ANAs. The new solid-phase assays detect up to 13 specific autoantibodies, while indirect immunofluorescence using Hep-2 cell substrate detects more than 100 clinically relevant autoantibodies, which is why the task force is making its recommendation.

The potential problem with screening sera for ANAs using the limited number of autoantigens that are present in solid-phase assays was illuminated in a recent case record of the Massachusetts General Hospital (NEJM. 2009; 360:711-720), where the diagnosis of systemic lupus erythematosus was significantly delayed because of a false-negative ANA test result that was determined using a non-indirect immunofluorescence method.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Over the past two years, the ACR ANA Taskforce—which was established as a result of the growing concerns ACR members had over this topic—has carefully reviewed the available literature concerning newer, solid-phase assays for the detection of ANAs. These solid-phase assays were developed to detect a limited number of specific autoantibodies in the serum of patients with autoimmune diseases. Although some of these tests have been approved by the Food and Drug Administration for use in screening for ANAs, the taskforce did not find sufficient evidence to conclude that solid-phase screening assays are equivalent to indirect immunofluorescent assays for the detection of ANAs.

Pages: 1 2 | Single Page

Filed Under: From the College, Practice Management Tagged With: antinuclear antibodies, Antinuclear antibody, Billing, Health Insurance, Rheumatoid arthritisIssue: October 2009

You Might Also Like:
  • Some Lupus Tests Yield False Results
  • New Study Reveals Limitations in ANA Test Kits for Lupus
  • Is Your Office Lab Up to Par?
  • 2018 CPT Coding Updates

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.